Oncolytics Biotech Launches Pivotal Phase 2 Colorectal Cancer Study REO 033

summarizeSummary

Oncolytics Biotech announced the initiation of REO 033, a randomized Phase 2 study for second-line RAS-mutant metastatic colorectal cancer, aiming to confirm prior compelling efficacy data for pelareorep.

check_boxKey Events

• Initiates Randomized Phase 2 Study

  Oncolytics Biotech launched the REO 033 study, a randomized Phase 2 trial evaluating pelareorep in second-line RAS-mutant microsatellite stable metastatic colorectal cancer patients.

• Aims to Confirm Strong Prior Efficacy

  The study is designed to confirm compelling efficacy data from the previous REO 022 study, which showed significantly improved median overall survival, progression-free survival, and objective response rates compared to standard-of-care.

• Fast Track Designation Received

  This study follows the recent Fast Track Designation granted by the FDA for pelareorep in 2L KRAS-mutant, MSS mCRC, underscoring the drug's potential in this indication.

• Preliminary Data Expected by Year-End

  The company anticipates initiating the first study site later this month and expects to provide preliminary data from the REO 033 trial by the end of 2026.

auto_awesomeAnalysis

This filing details the launch of a significant randomized Phase 2 study (REO 033) for pelareorep in metastatic colorectal cancer, directly following the company's recent strategic pivot to prioritize registrational trials. The study is designed to confirm previously observed strong efficacy data, which led to a Fast Track Designation. With preliminary data expected by year-end, this trial represents a crucial step in advancing pelareorep towards potential registration and could be a major value driver for the company.